Cromos Pharma, where the patients are

April 16, 2014 – News Bytes

CROs/Service Providers

Arsenal Capital acquires Synchrogenix for regulatory writing, submission services, will merge it with Certara

By Ronald Rosenberg
CenterWatch Staff Writer

Arsenal Capital Partners, a private equity firm that acquired software and scientific consulting services provider Certara last December, now has purchased Synchrogenix, an independent regulatory-writing CRO, and will merge the two.


The Pulse on Site Success By Jeffrey Adelglass, M.D.

Throughout the evolution of clinical trials, patient enrollment has remained the most confounding element of timely trial completion. From the site perspective, the challenges are many. It is critical to mobilize strategies that minimize cost, maximize recruitment and avert patient attrition.


More Pulse articles... »
CRF Health eCOA webinar series
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.